| Literature DB >> 22359481 |
Seul Ki Chan Lee1, Sang Min Park, Chaeuk Im.
Abstract
B13 analogues are being considered as therapeutic agents for cancer cells, since B13 is a ceramide analogue and inhibits ceramidase to promote apoptosis in cancer cells. B13 sulfonamides are assumed to have biological activity similar to B13, since they are made by bioisosterically substituting the carboxyl moiety of B13 with sulfone group. Twenty B13 sulfonamides were evaluated for their in vitro cytotoxicities against human colon cancer HT-29 and lung cancer A549 cell lines using MTT assays. Replacement of the amide group with a sulfonamide group increased cytotoxicity in both cancer cell lines. The sulfonamides with long alkyl chains exhibited activities two to three times more potent than that of B13 and compound (15) had the most potent activity with IC(50) values of 27 and 28.7µM for HT-29 and A549, respectively. The comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were used to carry out QSAR molecular modeling of these compounds. The predictive CoMSIA models for HT-29 and A549 gave cross-validated q2 values of 0.703 and 0.830, respectively. From graphical analysis of these models, we suppose that the stereochemistry of 1,3-propandiol is not important for activity and that introduction of a sulfonamide group and long alkyl chains into B13 can increase cytotoxicity.Entities:
Keywords: B13; Ceramide; Cytotoxicity; QSAR; Sulfonamides
Year: 2011 PMID: 22359481 PMCID: PMC3282231 DOI: 10.4196/kjpp.2011.15.6.423
Source DB: PubMed Journal: Korean J Physiol Pharmacol ISSN: 1226-4512 Impact factor: 2.016
Fig. 1Structure of ceramide and B13 analogues.
Structures and in vitro cytotoxicities of B13 sulfonamide analogues
The cells were plated at a density of approximately 1×104 cells/well in 96-well plates. Each well contained 180µl of medium into which 20µl of 10×concentration of prepared compounds or PBS were added. After 96h of culture, 0.1mg of MTT was added to each well and incubated at 37℃ for 4 h. The plates were centrifuged at 450×g to precipitate the formazan crystals. The medium was removed and 150µl of DMSO was added to each well to dissolve the formazan. In this assay, MTT was converted to blue formazan by mitochondrial dehydrogenase. The intensity of the blue color was measured with a microplate reader at a wavelength of 540 nm. The mean measured values are expressed as the IC50, the concentration that reduced the optical density of the treated cells by 50% with respect to the untreated controls.
Statistical data of CoMFA and CoMSIA models
aFields used (S, steric; E, electrostatic; H, hydrophobic; D, H-bond donor; A, H-bond acceptor); bq2, cross-validated correlation coefficient from leave-one-out (LOO); cN, optimum number of components; dSEP, standard error of prediction; er2ncv, non-cross-validated correlation coefficient; fSEE, standard error of estimate; gF, F-test value; hr2pred, predicted correlation coefficient.
Actual versus predicted cytotoxicities (pIC50) of the training set
aActual cytotoxic activity; bpredicted activity by the CoMSIA model with hydrophobic, hydrogen bond donor, and hydrogen bond acceptor fields; cdifference between the actual and predicted activities; The pIC50 (-log IC50) values were converted from IC50 values.
Actual versus predicted cytotoxicities (pIC50) of the test set
aActual cytotoxic activity; bpredicted activity by the CoMSIA model with hydrophobic and hydrogen bond acceptor fields; cdifference between the actual and predicted activities; The pIC50 (-log IC50) values were converted from IC50 values.
Fig. 2Graph of the actual versus predicted activities for training and test set compounds. (A) Colon cancer HT-29 cells. (B) Lung cancer A549 cells. The IC50 values were transformed into pIC50 (-log IC50) values (●: training set molecules, ▲: test set molecules).
Fig. 33D-contour maps of CoMSIA models. (A) CoMSIA model with hydrophobic, hydrogen bond donor, and hydrogen bond acceptor fields for colon cancer HT-29 cells. (B) CoMSIA model with hydrophobic and hydrogen bond acceptor fields for lung cancer A549 cells. Compound (15) is shown within the fields (yellow, favorable hydrophobicity; white, unfavorable hydrophobicity; cyan, favorable hydrogen bond donor; purple, unfavorable hydrogen bond donor; magenta, favorable hydrogen bond acceptor; red, unfavorable hydrogen bond acceptor).